Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E37.61 EPS (ttm)1.63 Insider Own1.80% Shs Outstand1.66B Perf Week4.34%
Market Cap101.68B Forward P/E34.17 EPS next Y1.79 Insider Trans115.22% Shs Float1.66B Perf Month4.23%
Income2.72B PEG3.13 EPS next Q0.41 Inst Own72.20% Short Float1.88% Perf Quarter19.47%
Sales16.06B P/S6.33 EPS this Y32.80% Inst Trans1.27% Short Ratio4.58 Perf Half Y29.57%
Book/sh9.13 P/B6.71 EPS next Y-0.39% ROA7.80% Target Price56.58 Perf Year17.12%
Cash/sh4.35 P/C14.08 EPS next 5Y12.01% ROE17.80% 52W Range45.63 - 61.20 Perf YTD17.84%
Dividend1.48 P/FCF94.68 EPS past 5Y-3.60% ROI10.70% 52W High0.16% Beta0.34
Dividend %2.41% Quick Ratio1.60 Sales past 5Y-1.50% Gross Margin74.40% 52W Low34.33% ATR1.11
Employees28000 Current Ratio1.70 Sales Q/Q-3.50% Oper. Margin22.50% RSI (14)67.33 Volatility2.32% 1.77%
OptionableYes Debt/Eq0.51 EPS Q/Q2.40% Profit Margin16.90% Rel Volume1.58 Prev Close60.79
ShortableYes LT Debt/Eq0.48 EarningsJan 22 BMO Payout87.20% Avg Volume6.82M Price61.30
Recom2.40 SMA203.54% SMA508.38% SMA20019.52% Volume10,743,337 Change0.84%
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-04-13Reiterated Argus Buy $46 → $54
Apr-26-13Reiterated MKM Partners Sell $26 → $29
Apr-15-13Reiterated Barclays Equal Weight $33 → $42
Jan-25-13Reiterated UBS Neutral $34 → $36
Jan-09-12Reiterated Barclays Capital Overweight $34 → $36
Oct-19-11Initiated MKM Partners Sell $26
Jun-27-11Reiterated UBS Neutral $28 → $30
Mar-31-11Downgrade Jefferies Buy → Hold $28.50
Mar-28-11Reiterated Barclays Capital Overweight $28 → $30
Sep-22-10Reiterated Deutsche Bank Buy $28 → $31.50
Sep-01-10Reiterated UBS Neutral $26 → $27
Aug-31-10Upgrade Jefferies Hold → Buy $28.80 → $30
Mar-12-10Initiated Jefferies & Co Hold $27
Dec-17-14 07:06PM  Cramer Remix: Here's what the Fed did today at CNBC
06:57PM  Lightning Round: Good stock with a good yield at CNBC
10:00AM  Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27 Business Wire
Dec-16-14 11:01AM  Jim Cramer: These Charts Prove It's Oil-and-Gas vs. Everything Else at TheStreet
Dec-11-14 11:27AM  Celgene's Abraxane Succeeds In Early Breast Cancer at Investor's Business Daily
08:01AM  Gilead Is Growing Fast And Its Stock Is Cheap at Barrons.com
Dec-10-14 11:04AM  Merck's Keytruda Might Treat Virulent Breast Cancer at Investor's Business Daily
06:00AM  Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors Business Wire
Dec-09-14 04:46PM  Lung Cancer Patients Say Don't Blame Us, Fund Us Bloomberg
04:30PM  Bristol-Myers Squibb Announces Dividend Business Wire
03:10AM  Small Group Behind Most Shareholder Proposals at The Wall Street Journal
Dec-08-14 05:30PM  US sues Deutsche in $190m taxes claim at Financial Times
04:10PM  Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data Zacks
01:37PM  Two Cancer Drugs for Hodgkin Lymphoma Shown Effective at The Wall Street Journal
01:35PM  Whats News: Business & Finance at The Wall Street Journal
01:30PM  Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects Business Wire
Dec-07-14 10:10PM  What's News: Business & Finance at The Wall Street Journal
12:39PM  Asia Corporate Watch at The Wall Street Journal
Dec-06-14 01:22PM  Two Cancer Drugs Shown Effective at The Wall Street Journal
01:00PM  Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma Business Wire
01:00PM  Merck, Bristol Immunotherapies Expand Strongly Into Blood Cancers at TheStreet
01:00PM  High rate of lymphoma patients respond to Bristol-Myers drug-study Reuters
Dec-05-14 04:25PM  A surprisingly stronger than expected monthly payroll report... Yahoo Finance Blogs
10:21AM  New Cancer Treatments Represent Major Breakthroughs -- But Who Is Going To Pay For Them? at Forbes
06:45AM  Biotech stocks to watch at ASH CNBC
Dec-04-14 01:20PM  James Allisons Cancer Research Breakthrough at MarketWatch
12:44PM  Immunotherapy: A Teacher's Journey to Health at MarketWatch
Dec-03-14 06:53PM  Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now at TheStreet
06:50PM  Cramer's play on pot at CNBC
03:45PM  AstraZeneca's (AZN) Iressa Accepted for Review in the U.S. Zacks
09:00AM  Bristol-Myers Squibb Foundation Awards Nine Grants Totaling More than $3.5 Million to Support Care for High-Risk Patients with Hepatitis B and C in China and India Business Wire
Dec-02-14 11:22AM  Avanir Stock Jumps On $3.5 Billion Otsuka Buyout at Investor's Business Daily
10:31AM  Jim Cramer on the Stock Market: Call Me a Skeptic, Not a Pessimist at TheStreet
Dec-01-14 11:03AM  Bristol-Myers Cuts Jobs in China as Drug Makers Rethink Marketing at The Wall Street Journal
09:00AM  Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Million in New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries Business Wire
Nov-27-14 12:00PM  Bristol-Myers Squibb's HCV Drug Daclatasvir Receives CRL Zacks
Nov-26-14 03:30PM  Five Prime Therapeutics Up on Deal with Bristol-Myers Zacks
02:33PM  Bristol-Myers: FDA blocks hepatitis C drug for now AP
12:29PM  Bristol-Myers Hepatitis C Drug Needs More Data on Combinations at Bloomberg
12:20PM  FDA Seeks More Data on Bristol-Myers Hepatitis C Therapy at The Wall Street Journal
11:56AM  FDA declines to approve Bristol-Myers hepatitis drug Reuters
11:34AM  Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C Business Wire
Nov-24-14 04:20PM  Five Prime in cancer drug deal with Bristol-Myers AP
01:05PM  A Buy Recommendation From Absolute Valuation Model to Bristol-Myers Squibb Gurufocus
08:59AM  Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types GlobeNewswire
08:59AM  Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types Business Wire
Nov-21-14 08:35AM  Thursdays Notable Options Activity Yahoo Finance Blogs
Nov-19-14 04:10PM  Celgene Up on Encouraging Long-Term Phase III Otezla Data Zacks
01:44PM  4 stocks to watch at MarketWatch
09:37AM  Screening Pharma Stocks Amid Turnaround YCharts
05:59AM  New PD-1 immune checkpoint inhibitor Opdivo (nivolumab) first to demonstrate survival benefit in Phase 3 trial in treatment naïve advanced melanoma CNW Group
Nov-18-14 05:26PM  Inovio-Roche End Deal for Development of Cancer Therapy Zacks
03:44PM  Novartis Presents Data on Heart Failure Candidate LCZ696 Zacks
04:48AM  [$$] India Divided on Whether to Break Bristol-Myers Drug Patent at The Wall Street Journal
02:00AM  Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions to Advance Biopharmaceutical Innovations From Leading U.S. Academic Research Institutions Business Wire
Nov-17-14 05:20PM  Bristol-Myers Squibb Reports Positive Opdivo Phase III Data Zacks
08:00AM  Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban) GlobeNewswire
08:00AM  Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA) Business Wire
01:28AM  New Bristol-Myers Drug Helped Skin-Cancer Patients in Trial Live Longer at The Wall Street Journal
Nov-16-14 04:45PM  Big Study Looks At Length of Drug Treatment After Stent Implantation at Forbes
03:45AM  [$$] Bristol-Myers Drug Shows Promise for Skin-Cancer Patients at The Wall Street Journal
03:45AM  Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial Business Wire
03:45AM  Bristol-Myers immunotherapy shows promise to replace chemo for melanoma Reuters
Nov-14-14 06:30AM  [$$] Bristol-Myers Plans Ireland Plant at The Wall Street Journal
06:00AM  Bristol-Myers Squibb to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland Business Wire
Nov-13-14 03:48PM  Can Gilead Recover from 3Q? at Barrons.com
12:06PM  3 Stocks Underperforming Today In The Drugs Industry at TheStreet
09:56AM  How Amazon is turning cloud computing into the new normal at Fortune
08:23AM  Analysts' Actions: Bristol-Myers, Broadcom, Jabil Circuit and More TheStreet
Nov-12-14 08:36AM  Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting Business Wire
Nov-10-14 11:14AM  Merck Down On Hepatitis C Data; Gilead Rises at Investor's Business Daily
09:00AM  Bristol-Myers Squibb Foundation Awards $2 Million in New Grants to Help Veterans and their Families Transition from Military to Civilian Life Business Wire
Nov-09-14 06:16PM  A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Gurufocus
Nov-08-14 09:00AM  Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis Business Wire
09:00AM  ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients Business Wire
Nov-07-14 01:44PM  Multiple Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 56th Annual American Society for Hematology (ASH) Meeting Business Wire
Nov-05-14 05:39PM  Prudential misses estimates as losses from derivatives soar Reuters
04:16PM  Prudential Financial profit halves as U.S. life business sags Reuters
02:22PM  Gabelli exec's 'crown jewel' picks for US investing at CNBC
01:15PM  White-Collar Workers Live Longer and the Gap Is Widening at BusinessWeek
Nov-04-14 04:30PM  Bristol-Myers Signs Option Deal to Acquire Galecto Biotech Zacks
10:00AM  Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference Business Wire
Nov-03-14 08:17PM  'Mom Turned Into a Monster': 10,000 Seniors Go Missing in Japan Bloomberg
03:28PM  Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized at The Wall Street Journal
09:18AM  [$$] Bristol-Myers Signs Option Agreement to Buy Galecto at The Wall Street Journal
08:30AM  Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis Business Wire
Oct-31-14 04:35PM  Bristol-Myers Squibb Up on Positive Opdivo Phase II Study Zacks
11:27AM  FDA Advisory Panel Gives Tepid Support To New Daiichi Sankyo Drug at Forbes
10:54AM  Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks TheStreet
10:54AM  Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks at TheStreet
10:20AM  AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook Zacks
07:55AM  Behind the big bearish bet on Bristol-Myers at CNBC
03:11AM  Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% Zacks
Oct-30-14 07:49PM  Cramer Remix: Apologies owed on Wall Street at CNBC +8.90%
07:14PM  Lung cancer drug promising Investor's Business Daily
06:35PM  Cramer: Best-of-breed stock picks circle back at CNBC
05:21PM  Market Thorns, Roses, All Time Highs, and ETF All Time Highs... Yahoo Finance Blogs
02:30PM  Bristol-Myers Squibb (BMY) Stock Is Gaining on Positive Phase 2 Results at TheStreet
01:04PM  BRISTOL MYERS SQUIBB CO Financials EDGAR Online Financials
01:00PM  Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement Business Wire
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company's principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliance with OliPass Corporation to discover and develop therapeutics against various targets using OliPass' technology platform. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREOTTI LAMBERTOChief Executive OfficerDec 05Sale60.3175,0004,522,944360,809Dec 05 05:39 PM
ANDREOTTI LAMBERTOChief Executive OfficerNov 05Sale57.7975,0004,334,153435,809Nov 07 05:13 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660245,112Nov 04 05:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,102099,666Nov 04 05:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 24Sale53.0050,0002,650,000510,809Oct 28 04:23 PM
CORNELIUS JAMES MDirectorOct 15Sale48.92100,0004,892,000169,041Oct 17 05:16 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 06Sale50.9950,0002,549,485560,809Oct 08 06:02 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,565Oct 06 05:52 PM
Cuss Francis MEVP & CSOSep 16Option Exercise25.1763,6671,602,575302,113Sep 16 05:18 PM
Cuss Francis MEVP & CSOSep 16Sale50.7763,6673,232,074238,446Sep 16 05:18 PM
Caforio GiovanniChief Operating OfficerSep 15Sale49.8726,6911,331,15540,755Sep 16 05:18 PM
Caldarella Joseph CSVP & ControllerSep 10Sale51.037,415378,37761,550Sep 10 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerSep 08Sale51.0550,0002,552,430610,809Sep 10 04:30 PM
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Option Exercise27.0119,650530,74759,652Jul 30 04:40 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Sale49.3225,7521,270,03733,900Jul 30 04:40 PM
DANIELS BRIANSVP Global Dev & Med AffairsJul 01Option Exercise0.004,671096,477Jul 02 06:35 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 05Option Exercise0.0013,9900662,469May 06 09:17 PM
Elicker John ESVP Pub Affairs & Inv RelationMay 03Option Exercise0.001,509050,536May 05 05:05 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000042,595May 02 04:18 PM
JUDGE ANN POWELLSVP, Human ResourcesApr 01Option Exercise0.001,55403,693Apr 03 04:17 PM
Caldarella Joseph CSVP & ControllerMar 13Sale55.209,137504,36268,965Mar 13 04:32 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.002,739058,345Mar 12 04:54 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.004,8780262,120Mar 12 04:52 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.001,173037,948Mar 12 04:53 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.00688043,432Mar 12 04:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.002,739011,600Mar 12 04:53 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.002,7390239,268Mar 12 04:51 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 10Option Exercise0.002,528092,314Mar 12 04:51 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.001,850049,399Mar 12 04:52 PM
Heller Frances KSVP, Business DevelopmentMar 10Option Exercise0.001,60904,402Mar 12 04:52 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.002,10702,107Mar 12 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.006,4100165,472Mar 12 04:50 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 10Option Exercise0.004,878068,910Mar 12 04:51 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.001,850078,768Mar 12 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0027,6130658,396Mar 12 04:50 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Sale55.818,799491,0638,861Mar 10 04:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Sale55.52100,0005,552,260630,783Mar 10 04:40 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724042,756Mar 10 04:42 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528017,224Mar 10 04:43 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390056,064Mar 10 04:43 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043036,841Mar 10 04:42 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 06Option Exercise0.003,010090,018Mar 10 04:41 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043047,630Mar 10 04:42 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400738,383Mar 10 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230159,626Mar 10 04:40 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 06Option Exercise0.002,889064,586Mar 10 04:40 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931077,422Mar 10 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100237,106Mar 10 04:41 PM
CORNELIUS JAMES MDirectorMar 05Sale55.82100,0005,582,000273,393Mar 05 04:40 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 03Option Exercise0.0099,9370292,758Mar 05 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 03Option Exercise0.0015,209040,530Mar 05 04:39 PM
Nielsen AnneChief Compliance & Ethics OffMar 03Option Exercise0.0013,132046,648Mar 05 04:39 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 03Option Exercise0.0017,471051,061Mar 05 04:37 PM
Cuss Francis MEVP & CSOMar 03Option Exercise0.0047,9530254,899Mar 05 04:36 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 03Option Exercise0.0050,3260103,410Mar 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 03Option Exercise0.00121,0140199,850Mar 05 04:35 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 03Option Exercise0.0018,875068,527Mar 05 04:36 PM
Caldarella Joseph CSVP & ControllerMar 03Option Exercise0.0031,053089,900Mar 05 04:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 03Option Exercise0.00423,5330912,318Mar 05 04:35 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 03Option Exercise0.0039,420068,820Mar 05 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyFeb 28Sale54.496,088331,73614,696Feb 28 04:44 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Option Exercise17.5139,363689,24691,316Feb 25 04:30 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Sale54.4441,5632,262,63849,753Feb 25 04:30 PM
Elicker John ESVP Pub Affairs & Inv RelationFeb 19Sale54.229,534516,91132,740Feb 19 04:25 PM
Cuss Francis MEVP & CSOFeb 18Option Exercise28.1138,6671,086,929237,037Feb 18 05:07 PM
Cuss Francis MEVP & CSOFeb 18Sale54.6129,8001,627,360207,237Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Option Exercise28.1115,000421,650206,345Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Option Exercise24.0036,251870,038130,266Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Sale54.3552,9632,878,28577,303Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Sale54.2810,490569,377195,855Feb 18 05:07 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Option Exercise28.11108,0003,035,880586,562Feb 11 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Sale52.6686,0754,532,572500,487Feb 11 04:30 PM
Caldarella Joseph CSVP & ControllerFeb 06Option Exercise19.4226,484514,20294,826Feb 06 05:28 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Option Exercise28.1118,750527,06381,989Feb 06 05:29 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Sale48.9328,4401,391,43353,549Feb 06 05:29 PM
Caldarella Joseph CSVP & ControllerFeb 06Sale48.9035,4711,734,45759,355Feb 06 05:28 PM
CAMPBELL LEWIS BDirectorFeb 05Option Exercise25.702,50064,2502,500Feb 05 05:37 PM
CAMPBELL LEWIS BDirectorFeb 05Sale48.282,500120,7120Feb 05 05:37 PM
CORNELIUS JAMES MDirectorFeb 04Sale48.90100,0004,890,000373,393Feb 04 05:00 PM
Caforio GiovanniEVP & Chief Commercial OfficerJan 03Option Exercise0.007,500054,817Jan 06 05:40 PM